Research Article

Genomic Analyses Identify Rare Variants in Genes Associated with Age at Menarche in Patients Affected with Anorexia Nervosa and Support a Role for Puberty Timing in Anorexia Nervosa Risk

Nicolas Lebrun¹, Philibert Duriez², Julia Clarke³, Philip Gorwood^{1,2}, Nicolas Ramoz¹, Thierry Bienvenu^{1,4},*

Received: 08 August 2020; Accepted: 10 August 2020; Published: 03 September 2020

Abstract

Puberty is a critical risk period for eating disorders, especially in girls. Previous reports showed that the association between puberty and eating disorders is mainly due to genetic factors, but the nature of these factors is unclear. To identify these genetic factors, we carried out exome analysis in 10 girls with anorexia nervosa compared to 10 unaffected women controls and identified low-frequency variants in genes among a list of 185 puberty-associated genes. After filtering data, 9 controls and 9 affected girls had at least one potential pathogenic rare (PPR) variant. In controls, 35 PPR variants were identified located (in 31 genes) whereas 52 PPR variants (in 38 genes) were identified in patients with AN. Among the genes identified only in the AN patients, we found a significant enrichment as compared to the general population and the control sample, in variants previously identified as associated with age at menarche (TNRC6A, LAMB2 and FAAH2). Two AN patients presented at least one rare missense variant in these genes. Moreover, nine patients with AN carried out missense/frameshift variants in puberty-associated genes previously identified by GWAS studies. Our results suggest that rare variants in genes

Volume 4, Issue 5

¹Université de Paris, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM UMR1266, « Genetic vulnerability to addictive and psychiatric disorders » team, Paris, France

²GHU Paris Psychiatrie et Neurosciences, CMME, Hôpital Sainte-Anne, F-75014 Paris, France

³Service de Psychiatrie de l'enfant et de l'adolescent, Hôpital Universitaire Robert Debré, Paris, France

⁴Laboratoire de Génétique et de Biologie Moléculaires, Hôpital Cochin, Assistance Publique- Hôpitaux de Paris-Centre Université de Paris, France

^{*}Corresponding Author: Dr. Thierry Bienvenu, Institut de Psychiatrie et de Neurosciences, 102 rue de la Santé, 75014 Paris, France, E-mail: thierry.bienvenu@inserm.fr

involved in the timing of puberty such as *TNRC6A*, *LAMB2* and *FAAH2* may predispose to anorexia nervosa susceptibility during puberty.

Keywords: Anorexia nervosa; Puberty; Exome; TNRC6A; LAMB2; FAAH2

1. Introduction

Puberty is the maturational process of the reproductive endocrine system that results in adult height and body proportion, in addition to the capacity to reproduce. The time of human puberty is highly variable, and sexually dimorphic. Known influences on the timing of this event in mammals include the light/dark cycle, lept in levels, and the increased expression of neurokinin B, kisspeptin, and their receptors, NK3R and KISS1R [1-3]. Moreover, over 20 genes carrying rare pathogenic variants have been identified in pubertal disorders, many of them encode critical components of the hypothalamic-pituitary-gonadal (HPG) axis [4]. Recent genome-wide association studies (GWAS) have also identified more than 100 candidate genes at loci associated with age at menarche (AAM) or voice breaking in males [5, 6].

Disordered pubertal timing affects up to 5% of adolescents and is associated with adverse health and psychosocial outcomes. Interestingly, early pubertal timing increases risk for eating disorders. For example, adolescents reporting a younger age at menarche are more likely to report bulimic symptomatology, and women with bulimia nervosa (BN) report an earlier age of menarche compared to women with anorexia nervosa (AN) or healthy controls. A population based study of adolescents also indicated that the median ages of onset for AN, BN and subthreshold eating disorders ranged between 12.3 and 12.6 years-old, which are quite similar to the average age of menarche in the general population (12.4 years-old) [7]. However, the mechanism by which pubertal timing increases risk for eating disorders is unclear. One of the major hypothesis is that the association between pubertal timing and eating disorders could be linked to common biological phenomena. Twin studies showed that eating disorder symptomatology is heritable. Genetic effects for eating disorders are also almost not present in prepubertal girls and increase markedly to approximately 50%-60% in advancing-pubertal girls and young adults [8-12]. Taken together, these findings raise the possibility that the genes involved in age of menarche play a role in the genetic influence on eating disorders. Up to now, only few studies showed that genetic factors that predispose girls to early menarche also increase eating disorders [13].

To better identify these genetic factors predisposing to eating disorders, we carried out an exome analysis in 10 girls with anorexia nervosa and in 10 unaffected women as controls, and searched for low-frequency variants among a list of 185 puberty-associated genes.

2. Participants

Patients with AN were recruited at the Clinique des Maladies Mentales et de l'Encéphale (CMME) (Hôpital Sainte-Anne, Paris, France). Diagnosis was made according to Diagnostic and Statistical Manual of Mental Disorders 5 (DSM5) scores. Individuals that consented to participation in the study had blood drawn for the collection of DNA and received a diagnostic interview administered by a trained research team member. Consensus diagnosis was obtained by agreement of clinicians specializing in AN. Eight individuals were considered as having a restrictive-subtype anorexia nervosa and two with the bulimia subtype. Three of these eating disorders (ED) patients are prepubertal at the time of the examination. Exclusion criteria included other types of ED than AN, confounding psychiatric diagnoses, for example, psychotic disorders, medical or neurological conditions causing weight loss. This cohort of patients consisted of 10 female individuals (13 to 47 years-old). Control group consists of 10 unaffected women. These controls were used to determine the frequency of rare variant in the different candidate genes.

3. Methods

3.1 Whole exome analysis

All individuals provided a signed informed written consent. Peripheral blood samples were collected from patients and controls in EDTA tubes. Genomic DNA was extracted from blood samples by a standard procedure using the Maxwell system (Promega, Madison, WI, USA) and the LEV DNA BLOOD AS 1290 kit (Promega, Madison, WI, USA). Whole exome capture, next-generation sequencing and data analysis were carried out by Cochin Institute and Paris Descartes Platform, respectively. Briefly, libraries were prepared from 3 µg genomic DNA extracted from whole blood using an optimized SureSelect Human Exome kit (Agilent) following the manufacturer's instructions. Captured, purified and clonally amplified libraries targeting the exome were then sequenced on a Nextseq 500 instrument (Illumina) according to the manufacturer's recommendations. Obtained sequence reads were aligned to the human genome (hg19) using BWA software. Downstream processing was carried out with the Genome analysis toolkit (GATK), SAMtools and Picard Tools (http://picard.sourceforge.net). Single-nucleotide variants and indels were subsequently called by the SAMtools suite (mpileup, beftools, vefutil). All calls with a read coverage ≤20× and a Phred-scaled SNP quality of \(\leq 20 \) were filtered out. We only searched for variants in a list of 185 pubertyassociated genes (23 genes with known mutations in patients diagnosed with Kallmann syndrome, normosmic hypogonadotrophic hypogonadism or precocious puberty; 145 candidate genes near genetic variants identified in large-scale GWAS studies for age at menarche in women; 7 genes associated with age at menarche; and 10 literature-based genes) [14-17]. Variants were annotated with an in-house Paris Descartes bioinformatics platform pipeline based on the Ensembl database (release 67). Four consecutive filters were applied to narrow down the variants: 1- exonic or located in consensus splice junction (+/- 2 bp); 2- non-synonymous; 3- located in a gene identified by an NM accession number (NM); and 4- minor allele frequency (MAF)<1% (in gnomAD database https://gnomad.broadinstitute.org/). In all cases, sequences variant in a gene are numbered starting from the first

doi: 10.26502/jppd.2572-519X0112

base of the ATG codon, numbering based on the reference sequence. Description of the sequence (Human Genome Variation Society, http://www.hgvs.org/mutnomen/recs.html) was done with the assistance of Alamut Visual software version 2.4.2 (Interactive Biosoftware, Rouen, France).

3.2 Sanger sequencing

DNA variants of interest were confirmed by PCR amplification and direct sequencing. DNA primer sequences and PCR conditions are available upon request to the corresponding author. Sequencing reactions were carried out with the BigDye Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems, Courtaboeuf, France) and loaded on the ABI 3130XL genetic analyser (Applied Biosystems, Courtaboeuf, France). Results were visualized using the Sequencher software (Gene codes, Ann Arbor, United States).

3.3 In silico analysis of missense variants

To find the influence of each missense variant on its protein structure that may have an important role in disease susceptibility, *in silico* analysis was performed. For each variant, bioinformatics tools (SIFT, MutationTaster, Polyphen-2) (https://www.interactive-biosoftware.com/alamut-visual/) were used to identify non-synonymous variant as possibly or probably damaging. These prediction tools are based on the degree of conservation of amino acid residues in sequence alignments derived from closely related sequences.

4. Results

4.1 Rare variants identified in AN patients

We performed exome sequencing for ten affected girls and 10 unaffected women as controls. In total 122,380 to 140,758 single nucleotide variants and 16,162 to 19,483 small deletions/insertions (1-10 bp) were identified across the exomes [18]. To identify genetic factors involved in anorexia and age of menarche, we search for low-frequency variants in genes among a list of 185 puberty-associated genes (Table 1). After filtering our data, it resulted in 9 affected individuals (9/10) at least one variant (no variant in patient NR279) (Table 2). In these patients, the number of variants varied from 2 (NR227) to 11(NR224) for each affected AN individual. In total, 52 variants were identified including 11 variants not previously described in all genomic databases (Table 2). One variant was a frameshift variant (*VGLL3*), two were in frame deletions (*SCRIB*, *GALNT10*) and all other variants were missense variants (Table 2). In total, variants were identified in 38 of the tested genes.

Decision (1971) 1	
Decomposition Composition	8 (methylation) 015 11 at 2016 (Manarcha timing) (disease genes)
Decision 1997 1	8 (methylation) 015 11 at 2016 (Manarcha timing) (disease genes)
Decision 1997 1	8 (methylation) 015 11 at 2016 (Manarcha timing) (disease genes)
Microscopy 10	8 (methylation) 015 11 at 2016 (Manarcha timing) (disease genes)
Decision	8 (methylation) 015 11 at 2016 (Manarcha timing) (disease genes)
December 1	8 (methylation) 015 11 at 2016 (Manarcha timing) (disease genes)
December 1985 198	8 (methylation) 015 015 (Manarcha timing) (disease genes)
Decision Column	8 (methylation) 015 015 (Manarcha timing) (disease genes)
Decision Column	8 (methylation) 015 015 (Manarcha timing) (disease genes)
December	015 at al. 2016 (Menarche timing) (disease genca)
Decision Column	015 at al. 2016 (Menarche timing) (disease genca)
March Marc	015 at al. 2016 (Menarche timing) (disease genca)
December 1977	015 at al. 2016 (Menarche timing) (disease genca)
Decision (1985) 1	515 61 al. 2016 (Manarcha timing) (disease genes) Vennacharisho et al. 2016 2013
Section Sect	015 st al. 2016 (Menarche timing) (disease genes) (Vermacheriko et al. 2016 2013
Material	015 st al. 2016 (Menarche timing) (d'sease genecs) (d'sease et al. 2016 2013
Section Sect	(disease gents) Yermachenko et al. 2016 2013
Section Company Comp	2013
March Marc	
March Marc	
Company Comp	
Company Comp	19 (sex-related disorders)
Mathematical Math	(disease genes) (disease genes)
Decision Column	Yermachenko et al. 2016
	8 (methylation)
	(disease genes)
150,0000011600 3 150,0000	(disease genes)
A	4 015
Additional Content Additional Addition	
Delicinosci S	
\$\frac{1}{2} \frac{1}{2} \fr	
1000000000000000000000000000000000000	(disease genes)
100000001999 3 100000000 50000000 50000000 500000000	(disease genes)
Decision 1972 1	015
	(disease genes) (disease genes)
DEGESSION 15	Elks et al. 2010
\$\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	(disease genes)
ENSCRIZZON 19927 X 33934-066 33939393 SPT 2 NRCES 1 NM (200475 5 NM (2	(disease genes)
ENSCRIZZON 19927 X 33934-066 33939393 SPT 2 NRCES 1 NM (200475 5 NM (2	
ENSQ000001182324 2 198324457 198342348 gQA.1 NR-AG2 NM_00188.4 NM_00188.6 Hou at al. 2017 ENSQ000000118833 1 2002/27614 200177420 q32.1 NR-SA2 NM_00188.0 NM_00188.0 Hou at al. 2017 ENSQ00000118802 9 137447873 137490334 q32.1 NR-SA2 NM_00188.0 NM_015537 Hou at al. 2017	(disease genes)
ENSIGNOSCO 1588CZ 9 137447575 137483534 624.3 NOME NW.,010557 PRO 44 al. 2017 ENSIGNOSCO 1588CZ 9 137447575 137483534 624.3 NOME NW.,010557 PRO 44 al. 2017 ENSIGNOSCO 1588CZ 9 137447575 137483534 624.3 NOME NOME NATURE NATUR	
	(disease genes)
ENSCO000105088 19 9853718 993852 613.2 OLEM2 MM 058164 House at all 2017	
\$850,000,001873 1 1990,0024 1999,000 621 1 0.0 ABS	
\$50,000,00179-68 \$ 980,0033 \$96,014.5 \$15 \$PGK NA 00,019.5 NM 00,049 No et al. 2017 No et al. 20	(disease genes)
ENSG0000002175 11 101029024 101129013 IQ22.1 PGR NNI_000206.4 NNI_00020 PRO NNI_00020	
ENSQ00000158585 11 45020223 46121178 pt1.2 PH21A NM_058621 hou eat 2017 ENSQ00000146675 5 68215756 68301821 qt3.1 PK3R1 NM_181523.3 NM_181523 Dumarah et al. ENSQ00000119596 2 197804093 198972891 qt3.1 PK2R1 NM_060226.4 NM_006226 hou et al. 2017	2013
ENSCORDO0115908 2 1976-94293 1987-9281 933.1 P.C.1.1 NML 0002294 NML 0002296 Hou et al. 2017.1 PML 0002294 NML 0002296 Hou et al. 2017.1 PML 0002297 NML 0002999 NML 000299 NML 000	t al. 2016 (Menarche timing)
ENSCOMMUNITIES 12 4000274 4001807 of 112 PRICALL NM 00273 5 NM 00273 Uninter at al. 2	(disease genes)
\$850,000,019411 3 7777965 7719026 913 PROUZ 94,01128 2 MA 0511918 2 MA	(disease genes)
ENSQ00000152707 9 8314246 10612723 p23 PTPRD NM 002840 5 NM 03280 Hou et al. 2017 ENSQ00000142940 1 43525187 4362368 p34.2 PTPRF NM 002840 5 NM 032840 Hou et al. 2017 ENSQ00000142944 6 177984779 13950974 p02 3 PTPRF NM 002840 5 NM 032840 Hou et al. 2017	
#5500000154994 1 4555197 4550969 594.2 PPRF NA 00045 5 MA 00050 the set at 2017 \$5000000154094 6 12986779 1500014 92.3 PPRF NA 00045 5 MA 00050 the set at 2017 \$50000000154000 7 15750000 158600074 (23.3 PPRF0 NA 00047.5 SMA 000507 Fung at 2017 \$5000000000034 3 9600007 550004 (23.3 PPRF0 NA 00047.5 SMA 000507 Fung at 2017 \$500000000034 3 MA 000507 Fung at 2017 \$50000000034 5 MA 000507 50004 (23.3 PPRF0 NA 00047.5 SMA 000507 Fung at 2017 \$500000000034 3 MA 000507 50004 (23.3 PPRF0 NA 00047.5 SMA 000507.5 SMA 000507.	8 (methylation)
ENSEQUOUDO(805)11 19 10013549 10022279 (613.2 ND:HS NM, 03125.4 NM, 0315725.4 NM, 0315725.4 NM, 030415 Hou et al., 2017. ENSEQUOUDO(805)1 19 7689049 7670465 (613.2 ND:HS NM, 030415.4 NM, 030415 Hou et al., 2017.	
ENSQ0000019866 9 81960711 84004074 021.32 RMIT NM_02945 Ptos at 8.2017 ENSQ0000009867 15 6048524 6122992 022 RORA NM_134261.3 NM_134261 Ptos at 8.2017 ENSQ0000019877 1 1 16500022 16544535 023.3 RORG NM_006917.5 NM_006917 Hou at 8.2017	
ENSG00000119042 2 19269500 199471286 q33.1 SATB2 NJL 07172500.2 NJL 07172500 Hou et al. 2017. PNSG00000190000 8 14739000 1494187273 doi: 3 CPR NJL 187725	
#8600000115941 1 17792998 17794993 05 2 85C168 NA 031377 Na u et 4 5977 Na 05 05 05 05 05 05 05 05 05 05 05 05 05	(disease genss)
FRSG000000142086 6 100389015 100484229 (416.3 SMH) NM, 005088 NM ON 484, 2017 ENSG000000142082 11 215000 29801 pt.5.5 SRT3 NM, 012239.6 NM, 012239 Mou et al. 2017	
5050000014022 11 271500 22901 151.5 8877 94 012228 94 027228 94 027228 94 027228 94 027228 94 027228 94 027228 94 027228 94 027228 94 02724 94	(disease genes)
ENSG00000163104 4 94207811 94291292 02.3 SMARCAD1 NM_020159 Hou et al. 2017 ENSG00000100146 22 3797688 37987422 013.1 SOX10 NM_008941.4 NM_008941 Hou et al. 2017	(disease genes)
ENSG00000181449 3 181711925 181714438 q26.33 SOX2 NM_003106.4 NM_003106 Hou et al. 2017 ENSG00000164211 5 111496033 111512900 q22.1 STARD4 NM_139164.3 NM_003308056 Hou et al. 2017	
ENGG00000168863 12 570:0000 57028885 1913 TACS 9M 019351.4 NM 0193	
ENSG00000149022 16 30085793 30091887 p11.2 TB398 NM_004608 Hou et al. 2017 ENSG00000081059 5 134114681 134151895 q31.1 TCF7 NM_003202.5 NM_003202 Hou et al. 2017	(disease genes) (disease genes), Lunetta et :
ENSCO0001516945 5 16758-0799 16824157 g34 TENM2 NN_0195243 NN_0195245 Hos of all 2017 ENSCO000151599 13 111311618 111344-09 g34 TEXAS TEXAS NN_019524 NN_019524 Hos of all 2017 ENSCO0000151590 3 24117153 24465758 g34.2 TH48 NN_00461 Hos of all 2017 NN_019524 NN_	(disease genes) (disease genes), Lunetta et
ENSCIONO144868 3 1990/6991 1990/792 6/2.1 TIMEMIN NW.003.51.4 NW.003.51 Hou et al. 2017	(disease genes) (disease genes), Lunetta et
ERSG00000195185 2 663877 677406 p25.3 TMEM18 NM, 152884.4 NM, 152884 Hou et al. 2017 ERSG00000196771 9 100915195 100119947 431.3 TMEM246 NM, 050124 NM, 050124 Hou et al. 2017 ERSG0000005909 9 105994641 105778629 p31.2 TMEM288 NM, 050124 NM, 050124 NM, 050124 NM, 050125 NM, 050124 NM, 0	(disease genes) (disease genes), Lunetta et
ENSG00000116783 1 74235387 7454428 p31.1 TNN3K NM_015078.3 NM_015078 Hou et al. 2017 ENSG00000000005 16 24610000 24627632 p12.1 TNROBA NM_014494.4 NM_014494 Lunetta et al. 20	(disease genes), Lunetta et
ENGO/0000198527 3 188914558 185938103 (27.2 TRA28 NM 00493.3 NM 00493.6 Hou et al. 2017 ENGO/0000198454 11 8912037 8950894 (15.4 TRM66 NM 0101717.2 NM 00101717.2 NM 00101	
-955(000000867) E 150686479 (200887) 02.22 (1907) M4 (000172.2 M4 (001077.2 No. 44 (001077.	
#565000019972 11 15145596 15187262 622 1 PPCB NA 506815 5 MA 00682 Nov et al. 2072 650500019972 1 1 15145596 15187266 622 1 PPCB NA 506815 5 MA 00682 Nov et al. 2072 6505000019975 3 68550000 4611595 627 11 TVV33 MA 153847 3 MA 153847 3 MA 153847 5 MA 00315 Nov et al. 2072 650500019975 3 6855000 4611595 67131 02078 MA 003155 MA 003155 Nov et al. 2072 6715000019975 4 6855000 4611595 07131 02078 MA 003155 MA 003155 Nov et al. 2072 6715000019975 MA 003155 Nov et al. 2072 6715000019975 NA 003155 Nov et al. 2072 6715000019975 NA 003155	015
#5650000011424 12 4784552 4794504 151.11 VPR M. OHDDR4 M. M. 000079 Nov et al. 277.11 VPL M. OHDDR4 M. M. 000079 Nov et al. 277.11 VPL M. OHDDR4 M. M. 014004 M. M. 014004 M. OHDDR4 M. OHDDR4 M. 014177 Nov et al. 277.11 VPL M. 01417 NOV et al. 277.11 VPL M. 01417 NOV et al. 277.11 VPL M. 01417 NOV et al. 277.11 VPL M.	015
ENGGIOXIOCI (1947) 3 14 (10,53794) 9 (10,53,53) 3 (50,52) 1 (10,53,52) 1 (10,53,5	015
ENGOQUOQ179214 17 69/2907 6124427 613.2 WSCD1 MM_015253 Pous et al. 2017 ENGOQUOQ198273 16 69782396 69941741 622.1 WSCD MVP2 NM_19424 Pous et al. 2017 ENGOQUOQ172822 5 43965176 4392021 612 28F131 MM_003432 Pous et al. 2017	015
ENSG00000173258 9 111525159 111577844 031.3 ZNF483 NM 133464.5 NM 133464 Hou et al. 2017	015
ENSG00000188511 22 49414524 49657542 q13.33 C22xrf34 NM_001289922 Hou et al. 2017	015
ENSG00000130758 19 40191426 40215575 [q13.2 MKL2/MAP9K1b/ML_000446.3 Hou et al. 2017	015 at al. 2016 (Mananche (ming) (disoase genes)

Table 1: List of the puberty-associated genes selected in the analysis of exome.

Family	Gene	Substitution	Variant	SIFT	Polyphen	gnomAD
NR147	CSMD1	c.2396C>G	T799S	Tolerated	Possibly damaging	Unknown
NR147	ESR1	c.16C>T	H6Y	Tolerated	Possibly damaging	915/279476
NR147	ALOX15B	c.769C>T	L257F	Deleterious	Probably damaging	958/2828487
NR147	GHR	c.469C>T	R157C	Deleterious	Benign	1107/282250
NR147	DST	c.3336G>C	E1112D	Tolerated Probably damaging		952/281446
NR147	MAGEL2	c.260C>T	P87L	Tolerated	Benign	Unknown
NR147	GALNT10	c.145_153dup	p.Pro49_Ala51dup			0.014
NR15	TNRC6A	c.4804G>A	G1602S	Tolerated	Probably damaging	60/282866
NR15	FAAH2	c.820C>T	R274C	Deleterious	Probably damaging	11/204712
NR15	NPTXR	c.1423T>C	W475R	Deleterious	Probably damaging	Unknown
NR15	GPRC5B	c.793G>T	D265Y	Deleterious	Probably damaging	192/282294
NR15	PROKR2	c.518T>G	L173R	Deleterious	Possibly damaging	621/282842
NR15	LAMB2	c.3674G>A	G1225D	Deleterious	Probably damaging	52/282050
NR15	PARP10	c.2170C>G	R724G	Tolerated		Unknown
NR180	PTPRD	c.2721G>T	M907I	Tolerated	Benign	Unknown
NR180	SIX6	c.385G>A	E129K	Deleterious	Probably damaging	1144/282412
NR180	BEGAIN	c.526G>A	D176N	Deleterious	Probably damaging	1240/253934
NR180	IGF2R	c.1063G>A	D355N	Tolerated	Benign	374/281644
NR191	LRP1B	c.7420G>A	G2474S	Deleterious	Possibly damaging	1548/281550
NR191	DST	c.5095G>A	E1699K	Tolerated	Probably damaging	103/282440
NR191	NPHP3	c.1714T>G	S572A	Tolerated	Benign	8/282696
NR191	PTPRN2	c.1969G>A	D657N	Tolerated	Possibly damaging	6/282600
NR191	CSMD1	c.9925G>T	A3309S	Deleterious	Benign	1/249044
NR195	NPHP3	c.3904G>T	p.A1302S	Tolerated	Probably damaging	Unknown
NR195	IMPG1	c.1228C>A	P410T	Tolerated	Possibly damaging	24/282378
NR195	WDR11	c.2962G>A	E988K	Deleterious	Possibly damaging	501/282436
NR195	LEKR1	c.822G>C	M274I	Tolerated	Benign	327/172706
NR195	PTPRN2	c.590C>G	A197G	Tolerated	Benign	987/277654
NR195	FLRT2	c.1174A>G	S392G	Tolerated	Benign	437/282752
NR224	VGLL3	c.357del	Glu119Aspfs*11			Unknown
NR224	VDR	c.1182T>A	N394K	Deleterious	Possibly damaging	Unknown
NR224	PTPRN2	c.2099A>C	H700P	Deleterious	Probably damaging	Unknown
NR224	TENM2	c.20G>A	R7Q	Deleterious	Possibly damaging	807/188400
NR224	TNRC6A	c.5042A>G	Y1681C	Deleterious	Benign	39/282846
NR224	TNRC6A	c.5779A>G	S1927G	Tolerated	Benign	22/272242
NR224	DST	c.3336G>C	E1112D	Tolerated	Probably damaging	952/281446
NR224	GALNT10	c.899C>T	P300L	Tolerated	Probably damaging	Unknown
NR224	NPHP3	c.2197A>G	K733E	Tolerated	Benign	1/251326
NR224	WWP2	c.1202A>G	H401R	Deleterious		1/111230
NR224	IGF2R	c.4471G>A	V1491M	Deleterious	Possibly damaging	4/251462
NR227	MKRN3	c.1457C>G	P486R	Tolerated	Benign	315/282892
NR227	PEX2	c.748T>C	W250R	Deleterious	Probably damaging	1487/282714
NR227	KDM3B	c.4739G>A	G1580D	Tolerated	Benign	11/282624
NR227	BRWD1	c.5893C>T	L1965F	Tolerated	Benign	542/282274
NR227	SCRIB	c.2076_2078del	p.Glu692del			0.0087
NR243	GHRHR	c.512C>G	T171S	Deleterious	Probably damaging	105/282854
NR243	RBM6	c.515C>T	P172L	Deleterious	Benign	829/282838
NR243	RBM6	c.997G>A	E333K	Deleterious	Probably damaging	829/282772
NR243	ALMS1	c.4984A>G	T1662A	Tolerated	Benign	13/249100
NR243	ALMS1	c.5186A>G	E1729G	Tolerated	Benign	235/280392
NR86	SCRIB	c.4063C>T	R1355W	Deleterious	Probably damaging	11/227118
NR86	UBA7	c.923C>T	P308L	Deleterious	Possibly damaging	Unknown

Table 2: Rare variants (<1% in NM_; <0.01% in gnomAD (in grey)) identified in 185 genes involved in puberty-associated genes in 10 patients affected by anorexia nervosa (2 bulimia type NR86 and NR180; 8 restrictive type).

In contrast, after filtering data, 9 healthy women (9/10) had at least one variant (no variant was observed in one control) (Table 3). In these subjects, the number of variants varied from 2 to 7 for each control individual. In total, 35 variants were identified including 6 variants not previously described in all genomic databases (Table 3). One variant was a frameshift variant (*BDNF*), and all other variants were missense variants (Table 3). In total, variants were identified in 31 candidate genes.

Family	Gene	Substitution	Variant	SIFT	Polyphen	gnomAD
DIP131	NFAT5	c.1687T>G	S563A	Benign	Benign	Unknown
DIP131	TAC3	c.248A>G	H83R	Deleterious	Possibly damaging	42/282842
DIP131	ARNTL	c.1600C>T	P534S	Tolerated	Possibly damaging	14/282434
DIP131	GHRHR	c.53C>T	P18L	Tolerated	Benign	31/185148
DIP231	ALOX15B	c.22G>A	V8M	Deleterious	Probably damaging	2/250166
DIP231	MAGEL2	c.1357G>A	D453N	Tolerated	Benign	1/249240
DIP40	EIF4G1	c.4085T>C	M1362T	Deleterious	Probably damaging	133/282808
DIP40	GALNT10	c.1535G>A	R512Q	Deleterious	Probably damaging	3/251458
DIP40	LRP1B	c.11966C>T	S3989F	Deleterious	Possibly damaging	75/282328
DIP40	UBA7	c.2516G>A	R839H	Tolerated	Benign	86/282146
DIP40	SEC16B	c.2180C>T	S727L	Tolerated	Benign	131/254428
DIP40	CADPS2	c.31T>C	S11P	Tolerated	Benign	12/129752
DIP48	DST	c.5948A>G	K1983R	Benign	Benign	Unknown
DIP48	LRP1B	c.13114A>T	N4372Y	Deleterious	Benign	1532/282098
DIP48	TCF7	c.353A>C	H118P	Deleterious	Probably damaging	Unknown
DIP48	CSMD1	c.6671C>T	T2224M	Tolerated	Probably damaging	45/279852
DIP60	BDNF	c.99_100delAT				1/234032
DIP60	SEC16B	c.3145C>T	R1049C	Benign	Probably damaging	7/248758
DIP60	TRPC6	c.172C>T	R58W	Deleterious	Benign	269/277716
DIP60	WSCD1	c.313C>T	R105C	Deleterious	Probably damaging	4/149526
DIP60	RAB29	c.407G>A	R136Q	Tolerated	Benign	4/251448
DIP60	WDR25	c.397C>T	R133C	Tolerated	Benign	1224/282792
DIP60	PTPRN2	c.590C>G	A197G	Tolerated	Benign	987/277654
DIP286	CSMD1	c.8935G>A	G2979S	Benign	Probably damaging	1522/279098
DIP286	ZNF131	c.535G>A	V179M	Tolerated	Benign	Unknown
DIP50	CADPS2	c.2440A>C	N814H	Deleterious	Probably damaging	4/248764
DIP50	PTPRD	c.2920C>T	P974S	Benign	Benign	Unknown
DIP50	UBA7	c.1525G>A	V509M	Deleterious	Possibly damaging	542/282784
DIP50	BRWD1	c.3802A>G	N1268D	Tolerated	Benign	3/248862
DIP50	HCRTR2	c.1178G>A	R393Q	Tolerated	Benign	7/250738
DIP509	NR0B1	c.686A>G	E229G	Tolerated	Benign	Unknown
DIP509	RMI1	c.1000A>G	K334E	Tolerated	Benign	910/282232
DRTT4541	DST	c.2011A>C	I671L	Tolerated	Benign	79/282636
DRTT4541	ALMS1	c.11638C>T	H3880Y	Tolerated	Benign	272/280380
DRTT4541	PRDM13	c.710C>T	A237V	Tolerated	Benign	768/174856

Table 3: Rare variants (<1% NM_; <0.01% in gnomAD (in grey)) identified in genes involved in puberty-associated genes in 10 unaffected women (in 9/10 women).

4.2 Prediction of pathogenicity of variants

Among the 52 puberty-related (PR) missense variants, 12 were considered as deleterious and probably damaging by all bioinformatic softwares. Among these potential pathogenic variants, two (*NPTXR*, *PTPRN2*) were not described in all genomic databases, and 4 (*FAAH2*, *LAMB2*, *GHRHR*, *SCRIB*) were considered as extremely rare (<0.1%). Moreover, 18 variants were considered as deleterious or probably damaging by one bioinformatic software (*GHR*, *DST* (*x3*), *TNRC6A* (*x2*), *PROKR2*, *LRP1B*, *CSMD1*, *NPHP3*, *WDR11*, *VDR*, *TENM2*, *GALNT10*, *WWP2*, *IGF2R*, *RBM6*, *UBA7*).

In contrast, in controls, among the 35 PR variants, only 6 were considered as deleterious and probably damaging by all bioinformatic softwares (*ALOX15B;EIF4G1; GALNT10; TCF7; WSCD1; CADPS2*). Among these potential pathogenic variants, only one (*TCF7*) was not described in all genomic databases, and all were considered as extremely rare (<0.1%). Moreover, 8 variants were considered as deleterious or probably damaging by one bioinformatic software.

4.3 Variants in candidate genes with significant sex-biases expression

The fact that AN patients were predominantly female (with nine females affected for each male case observed) and that onset of its condition is classically around puberty highly suggested that genes with sex biases expression were potential candidates to explain AN vulnerability. Recently, O'Brien and colleagues (http://dx.doi.org/10.1101/483636) identified 2726 autosomal transcripts with significant sex biases expression. Among these transcripts, we found 8 of our 38 candidate genes (CSMD1, TNRC6A, LRP1B, NPHP3, WDR11, PEX2, SCRIB, RBM6). Moreover, using the SAGD database (http://bioinfo.life.hust.edu.cn/SAGD), we found that 18 of our candidate genes were found to be sex-associated genes which varied expression between females and males in Human (PTPRD, CSMD1, VDR, GHRHR, MKRN3, HNF4A, ALOX15B, TENM2, PTPRK, SIX6, NPTXR, WSCD1, GPRC5B, PROKR2, LAMB2, UBA7, BEGAIN, GALNT10). Interestingly, BEGAIN, GALNT10, GHRHR, GPRC5B, HNF4A, LAMB2, MAGEL2, PTPRK, SIX6, UBA7, and VDR showed a pituitary-specific sex-biased expression [19].

5. Discussion

Puberty is a critical risk period for psychiatric disorders and more specifically for eating disorders (i.e., anorexia nervosa, bulimia nervosa) and their symptoms [7]. ED incidence increases across the pubertal period and becomes female predominant, and genetic influences on eating disorders significantly increase [20]. Ten years ago, a twin study showed that genetic factors might be important for pubertal risk for eating disorders in girls [21]. This study showed that there was essentially no genetic influence on eating disorder symptoms in pre-adolescent female twins, but significant genetic effects in twins during late adolescence. This conclusion was confirmed by two other twin studies [13, 22]. Moreover, investigations of shared genetic risk factors between eating disorder symptoms (e.g.,

overall eating disorder symptoms, dieting) and age at menarche or early pubertal timing showed that genetic risk factors (rather than environmental influences) entirely account for the co-occurrence of early menarche and eating disorder behaviors in girls [13].

To identify genetic factors that appear to become "activated" during the pubertal period increasing the phenotypic risk for AN in girls, we searched for rare variants in genes associated with age at menarche in 10 women affected by anorexia nervosa.

We identified an excess of rare variants in genes associated with age at menarche in AN patients as compared to controls. When its number is corrected by the total number of variant identified in the exome, the difference was not significant (Table 4). However, interestingly, we identified a significant enrichment of extremely rare variants and variants in genes previously identified associated with age of menarche (i.e. TNC6CA, LAMB2 and FAAH2) (Table 4) [15]. Indeed, in 2015, Lunetta and colleagues found that five missense variants (in ALMS1, LAMB2, TNRC6A, TACR3, PRKAGI) and two X-chromosome loci (IGSF1, FAAH2) were associated with age of menarche [15]. In the present study, one AN patient carried three rare variants in these genes (p.G1225D in LAMB2, p.G1602S in TNRC6A, and p.R274C in FAAH2) and another AN patient two rare variants in TNRC6A (p.Y1681C, p.S1927C). TNRC6A encodes a trinucleotide repeat-containing gene 6A protein, a member of the trinucleotide repeat containing 6 protein family. It functions in post-transcriptional gene silencing through the RNA interference (RNAi) and microRNA pathways [23]. It associates with messenger RNAs and Argonaute proteins in cytoplasmic bodies known as GW-bodies or P-bodies [24]. Variants identified in our two AN patients (NR15, NR224) were located in the Cterminal part of the protein (amino acids 1603-1622, PABPC1-interacting motif-2), known to be important for translational repression, and may impair RNAi and microRNA-induced gene silencing affecting metabolic pathways [25]. LAMB2 encodes the Laminin subunit beta-2 protein, a member of the family of extracellular matrix glycoproteins, major non collagenous constituent of basement membranes implicated in a wide variety of biological processes including cell adhesion, differentiation, migration, signaling, and neurite outgrowth. Recently, compound heterozygous missense variants were identified in patients with congenital nephrotic syndrome, ocular abnormalities and neurodevelopmental delay [26]. Interestingly, Laminin b2 is highly expressed during pituitary development and may explain the abnormal parenchyma of the anterior pituitary gland in this patient. Taking into account the role of the hypothalamus-pituitary-adrenal axis in eating disorders, variant in LAMB2 may play a role in the biological vulnerability to ED. Finally, FAAH2 encodes the Fatty acid amide hydrolase 2 (EC 3.5.1.99, oleamide hydrolase 2, anandamide amidohydrolase 2), a member of the serine hydrolase family of enzymes. Fatty acid amide hydrolase 2 degrades endocannabinoids and defects in this enzyme have been associated with neurologic and psychiatric disorders [27]. Patient carrying the missense variant p.A458S in this gene presented hypotonia, autistic features, seizures, but also anxiety disorder, suicidal ideas and feeding difficulties. Interestingly, we previously identified a rare variant (p.H312N) at the hemizygous state in a male patient with AN [28].

Parameters	Anorexia nervosa (n=10)	Healthy Controls (n=10)	p Value
Number of mutated individuals	9	9	-
Number of variants per individual	2 to 11	2 to 7	-
Number of total variants (<5%) in the exome	14692	13536	-
Number of total variants (<1%) in the exome	10307	9489	0.1487
Number of variants	52	35	0.1494
Number of unknown variant	11	6	0.6991
Number of mutated genes	38	31	0.0802
Number of deleterious variants	13	6	0.3844
Number of extremely rare variants	19	20	0.0581
Number of variants in genes associated with age of menarche*	5	0	0.0588
Number of variants in puberty diseases genes**	4	2	0.7211
Number of variants in GWAS candidate genes***	29	32	0.0004
Number of variants in literature-based genes §	3	1	0.5248

Table 4: Comparison between the frequency of variants (taking into account their frequency in gnomAD database) in the cohort of AN patients and of control women.* genes associated with age of menarche (n=7) (15), ** genes involved in rare Mendelian disorders of puberty (n=23) [29], *** genes associated with age of menarche (n=145) [29], \$ Literature-based genes [16-17, 30-32] (n=10).

In the present study we identified rare variants in genes initially associated with age of menarche by GWAS analysis and confirmed by other approaches. This is the case for *MKRN3* (NR227) and *VGLL3* (NR224).Up to now, one of the most relevant gene underlying central precocious puberty (CPP) is the makorin ring finger protein 3 gene (*MKRN3*) [33]. MKRN3 is a single-exon, maternally imprinted gene, which is expressed only from the paternal allele. Consequently, only paternally-inherited loss-of-function mutations in MKRN3 cause CPP. Interestingly, MKRN3 is expressed in the mouse and human hypothalamus, a structure containing integrative systems that support physiological processes such as food intake and energy expenditure [34]. VGLL3 is a transcriptional co-factor that binds TEAD family transcription factors to regulate events ranging from wing development in fly, to muscle fibre composition and immune function in mice. Interestingly, Vgll3 play a role in the sex-biased disorders such as autoimmune diseases and may participate to the sex-biased rate of anorexia nervosa. We hypothesize that these genes account for, at least part of, the underlying shared genetic factors between age at menarche and eating disorders [13].

We also identified 29 GWAS puberty-associated genes via coding variation, without significant enrichment as compared to general population and our control sample including 10 unaffected women. The majority of these genes

doi: 10.26502/jppd.2572-519X0112

are localized in candidate regions for age of menarche and puberty, but were not clearly involved in puberty. For example, this is the case for the rare variant in *PTPRN2* (NR224). PTPRN2 is also known la-2beta and was identify as a candidate associated with pediatric obesity [35, 36].

6. Conclusions

To conclude, although pubertal timing increases risk for eating disorders, the nature of the association between pubertal timing and eating disorders is unclear [37-39]. Puberty involves many physical, psychological, and emotional changes all of which likely play an important and complex role in the association between pubertal timing and eating disorders. The genes involved in puberty timing likely interact with aspects of the environment to increase vulnerability to develop ED at puberty, and previous reports have shown that the association between puberty and eating disorders is due to genetic factors [13]. Our results suggest that rare variants in genes involved in puberty timing such as *TNRC6A*, *LAMB2* and *FAAH2* may contribute to the vulnerability to AN during puberty and support causal links with anorexia nervosa susceptibility.

Disclosure and Conflict of Interest

The authors report no conflict of interest.

Funding Source

This study was supported by Institut National de la Recherche Médicale INSERM and by Fondation Maladies Rares.

Acknowledgments

We thank the patients for their enthusiastic participation and all physicians from the different medical and psychiatric centres.

Credit Author Statement

Thierry Bienvenu and Nicolas Ramoz had full access to all data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Concept and Design: Thierry Bienvenu, Nicolas Ramoz; Acquisition, analysis and interpretation of the data: Thierry Bienvenu, Nicolas Lebrun, Philip Gorwood, Nicolas Ramoz; Drafting of the manuscript: Thierry Bienvenu, Philip Gorwood, Nicolas Ramoz; Patient's inclusion: Julia Clarke, Philibert Duriez; Technical analysis: Nicolas Lebrun.

Compliance with Ethical Standards

Ethical approval All procedures performed in this study were in accordance with the ethical standards of our national research committee (Comité Protection Personnes Paris Pitié Salpétrière N°33-03) and with the 1964

Helsinki declaration and its later amendments. Informed written consent was obtained from all patients included in the study.

References

- Mantzoros CS, Flier JS, Rogol AD. A longitudinal assessment of hormonal and physical alterations during normal puberty in boys. V. Rising leptin levels may signal the onset of puberty. J. Clin. Endocrinol. Metab 82 (1997): 1066-1070.
- 2. Cesario SK, Hughes LA. Precocious puberty: a comprehensive review of literature. J. Obst. Gynecol. Neonat. Nursing 36 (2007): 263-274.
- 3. Hughes IA. Releasing the brake on puberty. N. Engl. J. Med 368 (2013): 2513-2515.
- 4. Abreu AP, Kaiser UB. Pubertal development and regulation. Lancet Diabetes Endocrinol 4 (2016): 254-264.
- 5. Day FR, Thompson DJ, Helgason H, et al. Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk. Nat. Genet 49 (2017): 834-841.
- 6. Witchel SF. Genetics, Genome-Wide Association Studies, and Menarche. Sem.Reprod. Med 34 (2016): 205-214.
- 7. Hayward C, Killen JD, Wilson DM, et al. Psychiatric risk associated with early puberty in adolescent girls. J.Am. Acad. Child Adolesc. Psychiatry 36 (1997): 255-262.
- 8. Klump KL, Kaye WH, Strober M. The evolving genetic foundations of eating disorders. Psy. Clin. North Am 24 (2001): 215-225.
- 9. Klump KL, McGue M, Iacono WG. Differential heritability of eating attitudes and behaviors in prepubertal versus pubertal twins. Int. J. of Eat. Disord 33 (2003): 287-292.
- Gorwood P, Kipman A, Foulon C. The human genetics of anorexia nervosa. Eur. J. Pharmacol 480 (2003): 163-170.
- 11. Culbert KM, Burt SA, McGue M, et al. Puberty and the genetic diathesis of disordered eating attitudes and behaviors. J. Abnormal Psy 118 (2009): 788-796.
- 12. Klump KL, Culbert KM, Slane JD, et al. The effects of puberty on genetic risk for disordered eating: evidence for a sex difference. Psy. Med 42 (2012): 627-637.
- 13. Baker JH, Thornton LM, Bulik CM, et al. Shared genetic effects between age at menarche and eating disorders. J. Adolesc Health 51 (2012): 491-496.
- 14. Elks CE, Perry JR, Sulem P, et al. Thirty new loci for age at menarche identified by a metaanalysis of genome-wide association studies. Nat. Genet 42 (2010): 1077-1085.
- 15. Lunetta KL, Day FR, Sulem P, et al. Rare coding variants and X-linked loci associated with age at menarche. Nat. Commun 6 (2015): 7756.

- 16. Yermachenko A, Dvornyk V. UGT2B4 previously implicated in the risk of breast cancer is associated with menarche timing in Ukrainian females. Gene 590 (2016): 85-89.
- 17. Yang L, Li L, Peters SAE, et al. Age at Menarche and Incidence of Diabetes: A Prospective Study of 300,000 Women in China. Am. J. Epidemiol 187 (2018): 190-198.
- 18. Bienvenu T, Lebrun N, Clarke J, et al. De novo deleterious variants that may alter the dopaminergic reward pathway are associated with anorexia nervosa. Eat Weight Disord (2019).
- 19. Kassam I, Wu Y, Yang J, et al. Tissue-specific sex differences in human gene expression. Hum. Mol. Genet 28 (2019): 2976-2986.
- 20. Hudson JI, Pope HG Jr. Genetic epidemiology of eating disorders and co-occurring conditions: the role of endophenotypes. Int. J. Eat Disord 40 (2007): S76-S78.
- 21. Klump KL, Keel PK, Sisk C, et al. Preliminary evidence that estradiol moderates genetic influences on disordered eating attitudes and behaviors during puberty. Psy. Med 40 (2010): 1745-1753.
- 22. Harden KP, Mendle J, Kretsch N. Environmental and genetic pathways between early pubertal timing and dieting in adolescence: distinguishing between objective and subjective timing. Psy. Med 42 (2012): 183-193.
- 23. Nishi K, Nishi A, Nagasawa T, et al. Human TNRC6A is an Argonaute-navigator protein for microRNA-mediated gene silencing in the nucleus. RNA 19 (2013): 17-35.
- 24. Suzawa M, Noguchi K, Nishi K, et al. Comprehensive Identification of Nuclear and Cytoplasmic TNRC6A-Associating Proteins. J. Mol. Biol 429 (2017): 3319-3333.
- 25. Zipprich JT, Bhattacharyya S, Mathys H, et al. Importance of the C-terminal domain of the human GW182 protein TNRC6C for translational repression. RNA 15 (2009): 781,793.
- 26. Tahoun M, Chandler JC, Ashton E, et al. Mutations in LAMB2 associate with albuminuria and Optic Nerve Hypoplasia with Hypopituitarism. J. Clin. Endocrinol. Metab (2019): dgz216.
- 27. Sirrs S, van Karnebeek CD, Peng X, et al. Defects in fatty acid amide hydrolase 2 in a male with neurologic and psychiatric symptoms. Orphanet J Rare Dis 10 (2015): 38.
- 28. Lombardi L, Blanchet C, Poirier K, et al. Anorexia nervosa is associated with Neuronatin variants. Psy. Genet 29 (2019): 103-110.
- 29. Hou H, Uusküla-Reimand L, Makarem M, et al. Gene expression profiling of puberty-associated genes reveals abundant tissue and sex-specific changes across postnatal development. Hum. Mol. Genet 26 (2017): 3585-3599.
- 30. Demerath EW, Liu CT, Franceschini N, et al. Genome-wide association study of age at menarche in African-American women. Hum. Mol. Genet 15 (2013): 3329-3346.
- 31. Pyun JA, Kim S, Cho NH, et al. Genome-wide association studies and epistasis analyses of candidate genes related to age at menarche and age at natural menopause in a Korean population. Menopause 21 (2014): 522-529.

- 32. Cohen E, Belkacem S, Fedala S, et al. Contribution of functionally assessed GHRHR mutations to idiopathic isolated growth hormone deficiency in patients without GH1 mutations. Hum. Mutat 40 (2019): 2033-2043.
- 33. Valadares LP, Meireles CG, De Toledo IP, et al. MKRN3 Mutations in Central Precocious Puberty: A Systematic Review and Meta-Analysis. J. Endocr. Soc 3 (2019): 979-995.
- 34. Florent V, Baroncini M, Jissendi-Tchofo P, et al. Hypothalamic structural and functional imbalances in anorexia nervosa. Neuroendocrinology (2019).
- 35. Selvanayagam T, Walker S, Gazzellone MJ, et al. Genome-wide copy number variation analysis identifies novel candidate loci associated with pediatric obesity. Eur. J. Hum. Genet 26 (2018): 1588-1596.
- 36. Lee S. The association of genetically controlled CpG methylation (cg158269415) of protein tyrosine phosphatase, receptor type N2 (PTPRN2) with childhood obesity. Sci. Rep 9 (2019): 4855.
- 37. Stice E, Presnell K, Bearman S. Relation of early menarche to depression, eating disorders, substance abuse, and comorbid psychopathology among adolescent girls. Dev. Psy 37 (2001): 608-619.
- 38. Kaltiala-Heino R, Marttunen M, Rantanen P, et al. Early puberty is associated with mental health problems in middle adolescence. Soc. Sci. Med 57 (2003): 1055-1064.
- 39. Klump KL. Puberty as a critical risk period for eating disorders: a review of human and animal studies. Hormones Behav 64 (2013): 399-410.

Citation: Nicolas Lebrun, Philibert Duriez, Julia Clarke, Philip Gorwood, Nicolas Ramoz, Thierry Bienvenu. Genomic Analyses Identify Rare Variants in Genes Associated with Age at Menarche in Patients Affected with Anorexia Nervosa and Support a Role for Puberty Timing in Anorexia Nervosa Risk. Journal of Psychiatry and Psychiatric Disorders 4 (2020): 293-306.

